Galil Medical

Company Overview

Snapshot

Founded in January 1997, Galil Medical operated with 1–10 employees. The company secured $52 million across one disclosed funding round from three investors. A significant milestone for the company was its acquisition by BTG plc in May 2016.

Business overview

Galil Medical develops cryotherapy solutions for various medical conditions, focusing on cancer treatment. Its core technology utilizes the Joule-Thomson effect with compressed argon gas to create extremely low temperatures, ablating diseased tissue through freezing. The company's systems are designed to treat conditions affecting the kidneys, liver, lungs, prostate, and bones, as well as targeted pain and nerve applications, serving the healthcare and life sciences sectors.

Strategic signal

In May 2016, Galil Medical was acquired by BTG plc for $110 million. This acquisition highlights the strategic value of its cryotherapy technology within the medical devices market, signaling a successful exit for investors and a consolidation within the health tech and life sciences sector.

Company Intelligence Q&A

What was a significant financial event for Galil Medical?

Galil Medical was acquired by BTG plc for $110 million in May 2016. This event marked a successful exit for the company and its investors.

When was Galil Medical founded?

Galil Medical was founded in January 1997, establishing its presence in the medical technology sector.

What is Galil Medical's primary focus?

Galil Medical specializes in developing cryotherapy solutions for cancer treatment and other medical conditions, utilizing freezing technology to ablate diseased tissue.

Which investors participated in Galil Medical's funding rounds?

In December 2006, Galil Medical received funding from.

What is the core technology behind Galil Medical's products?

Galil Medical's core technology is based on the Joule-Thomson effect, using compressed argon gas to produce extremely low temperatures for cryoablation, effectively destroying targeted tissue.